TrialJournal for immunotherapy of cancer2025

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.

Caroline Even et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.